Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 14, 2016 1:23 AM ET


Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory d...

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

49 Employees





Key Executives for aTyr Pharma Inc.

Chief Executive Officer and Director
Age: 55
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

aTyr Pharma Inc. Key Developments

aTyr Pharma, Inc. Provides Update on Corporate Developments

aTyr Pharma Inc. provided an update on corporate developments. The company completed patient dosing for Phase 1b/2 trial for Resolaris in adult FSHD patients. The company announced that it has completed patient dosing for its Phase 1b/2 trial for Resolaris in adult FSHD patients and is in the process of database curation and analysis. The company expects to report data at approximately the end of the first quarter of 2016. The study is a double-blind, placebo-controlled, multiple ascending dose trial at multiple sites in the European Union and United States, and is designed to evaluate safety, tolerability, pharmacokinetics and the biological activity of Resolaris in adult patients with FSHD; first patients dosed in Phase 1b/2 trial of Resolaris in patients with LGMD2B. The first patients have been dosed in the recently initiated Phase 1b/2 trial of Resolaris in patients with LGMD2B. The international trial is an open-label, intra-patient dose escalation study designed to assess the safety, tolerability, immunogenicity and activity of Resolaris in adult patients with LGMD2B and adult patients with FSHD. The trial will further augment the company's blinded Phase 1b/2 clinical trial of Resolaris in adult patients with FSHD and inform subsequent later-stage trial considerations; started process development for GMP manufacturing in E. coli and commenced preclinical IND-enabling studies for second IND candidate. For aTyr's second IND candidate, iMod.Fc, the company started process development for GMP manufacturing in E. coli, as well as preclinical IND-enabling studies. iMod.Fc represents the first, engineered Physiocrine-based product candidate. It is based on an immuno- and fibro-modulating Physiocrine domain fused to an Fc region of a human antibody. iMod.Fc has shown promising activity in a well-established preclinical rodent model of lung inflammation and pulmonary fibrosis; anticipating initiation of clinical program in rare pulmonary diseases with an immune component (RPIC). aTyr plans to initiate a clinical program in RPIC in patients with interstitial lung disease (ILD). Later this year, the company will make a determination as to whether to move forward with an exploratory Phase 1b/2 trial for Resolaris (by the end of 2016) and/or iMod.Fc (in 2017) in one or more ILD indications.

aTyr Pharma Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:30 AM

aTyr Pharma Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: John D. Mendlein, Chief Executive Officer and Director.

aTyr PharmaAppoints Sanuj Ravindran, M.D., as Chief Business Officer

aTyr Pharma Inc. announced that Sanuj Ravindran, M.D., has joined the company as Chief Business Officer. Dr. Ravindran will lead aTyr's corporate development and strategy efforts, including the planning and execution of strategic growth initiatives as the company advances its mission to make meaningful medicines for patients with serious diseases. In Dr. Ravindran's most recent role as Senior Vice President and Global Head, Corporate Development at The Medicines Company.

Similar Private Companies By Industry

Company Name Region
AbbVie Biotherapeutics Inc. United States
Nutech Medical, Inc. United States
Centrexion Corp United States
Life Science Institute, LLC United States
Choncept LLC United States

Recent Private Companies Transactions

Private Placement
March 31, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact aTyr Pharma Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at